Sunovion   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Marlborough MA United States (1984)
Status: Acquired by Sumitomo Dainippon (2009)

Organization Overview

First Clinical Trial
2000
NCT00667407
First Marketed Drug
1999
levalbuterol (xopenex)
First NDA Approval
1999
levalbuterol (xopenex)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Elevation Pharmaceuticals, Inc.(now known as Sunovion Respiratory Development Inc.) | Elevation Pharmaceuticals, Inc., (now known as Sunovion Respriatory Developement Inc.) | Sepracor | Sepracor Incorporated, 84 Waterford Drive, Marlborough, MA 01752 | Sunovioin | Sunovion | SUNOVION | Sunovion Pharamceuticals Inc. | Sunovion Pharmacetuicals Inc. | Sunovion Pharmaceuticals | Sunovion Pharmaceuticals In. | SUNOVION PHARMS INC | SUNOVION RESP | Sunovion Respiratory Development | Sunovion Respiratory Development Inc. | Sunovion Respiratory Director

Active Ingredients

Marketed Drugs (9)

apomorphine (apokyn) (2020)

arformoterol (brovana) (2006 NDA)

eslicarbazepine acetate (aptiom) (2013 NDA)

eszopiclone (lunesta) (2004 NDA)

glycopyrronium (robinul) (2015)

indacaterol (arcapta neohaler) (2011)

levalbuterol (xopenex) (1999 NDA)

lurasidone (latuda) (2010)

zonisamide (Zonegran) (2000)

Drugs in Phase 4 Trials (16)

Key: Sunovion (15) Acquired (1)

albuterol (proventil) (16 trials)

arformoterol (brovana) (16 trials)

bupropion (wellbutrin) (1 trial)

carbamazepine (tegretol) (1 trial)

ciclesonide (alvesco) (13 trials)

escitalopram (lexapro) (1 trial)

eslicarbazepine acetate (aptiom) (7 trials)

eszopiclone (lunesta) (34 trials)

glycopyrronium (robinul) (8 trials)

haloperidol (haldol) (2 trials)

levalbuterol (xopenex) (22 trials)

lurasidone (latuda) (42 trials)

perphenazine (trilafon) (1 trial)

salmeterol (serevent) (5 trials)

tiotropium (spiriva) (4 trials)

zolpidem (ambien) (1 trial)

Drugs in Phase 3 Trials (13)

apomorphine (apokyn) (6 trials)

dasotraline (13 trials)

formoterol (foradil) (2 trials)

lithium (lithonate) (1 trial)

mometasone (elocon) (3 trials)

olanzapine (zyprexa) (3 trials)

quetiapine (seroquel) (5 trials)

risperidone (risperdal) (3 trials)

sep-4199 (2 trials)

Ulotaront (18 trials)

urea (1 trial)

valproic acid (depakene) (1 trial)

venlafaxine (effexor) (2 trials)

Drugs in Phase 2 Trials (8)

Key: Sunovion (5) Acquired (3)

aclidinium (tudorza pressair) (1 trial)

afacifenacin (1 trial)

ep-101 (2 trials)

ipratropium (atrovent) (2 trials)

moxifloxacin (avelox) (2 trials)

radequinil (1 trial)

sb623 (1 trial)

seribantumab (1 trial)

Drugs in Phase 1 Trials (10)

Key: Sunovion (9) Acquired (1)

amisulpride (BARHEMSYS) (1 trial)

aripiprazole (abilify) (2 trials)

dsp-1053 (1 trial)

dsp-8658 (1 trial)

eo-3021 (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

metformin (glucophage) (1 trial)

norgestimate (1 trial)

sep-228432 (1 trial)

wt2725 (1 trial)

Indications

Approved Indications


 

Asthma

Emphysema

Epilepsy, Partial, Sensory

Pulmonary Disease, Chronic Obstructive

Seizures

Sleep Initiation and Maintenance Disorders

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Alzheimer Disease (Phase 2)

Anxiety Disorders (Phase 4)

Apnea (Phase 4)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Asthma (Phase 4)

Asthma, Exercise-Induced (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Autistic Disorder (Phase 3)

Back Pain (Phase 4)

Binge-Eating Disorder (Phase 3)

Bipolar Disorder (Phase 3)

Bronchial Hyperreactivity (Phase 3)

Bronchial Spasm (Phase 3)

Bronchitis (Phase 4)

Bronchitis, Chronic (Phase 4)

Bulimia (Phase 3)

Cerebral Infarction (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Disease (Phase 4)

Emphysema (Phase 4)

Epilepsies, Partial (Phase 3)

Epilepsy (Phase 4)

Feeding and Eating Disorders (Phase 3)

Fibromyalgia (Phase 4)

Hyperkinesis (Phase 3)

Inflammation (Phase 2)

Ischemia (Phase 2)

Low Back Pain (Phase 4)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Mental Disorders (Phase 2)

Migraine Disorders (Phase 4)

Myofascial Pain Syndromes (Phase 4)

Neoplasms (Phase 1)

Parasomnias (Phase 4)

Parkinson Disease (Phase 3)

Psychotic Disorders (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Emphysema (Phase 4)

Respiratory Aspiration (Phase 3)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 3)

Schizophrenia (Phase 4)

Seizures (Phase 4)

Sleep Apnea, Obstructive (Phase 4)

Sleep Apnea Syndromes (Phase 4)

Sleep Initiation and Maintenance Disorders (Phase 4)

Sleep Wake Disorders (Phase 4)

Status Asthmaticus (Phase 4)

Stroke (Phase 2)

Syndrome (Phase 4)

Tobacco Use Disorder (Phase 4)

Urinary Bladder, Overactive (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 192
  • # of Trial APIs: 47